{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:34:04Z","timestamp":1792190044379,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.vaccine.2023.04.049","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T03:08:36Z","timestamp":1682392116000},"page":"3813-3823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-7752","authenticated-orcid":false,"given":"Miao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"V\u00e4is\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-8167","authenticated-orcid":false,"given":"Pekka","family":"Kolehmainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moona","family":"Huttunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seppo","family":"Meri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"\u00d6sterlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Julkunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2023.04.049_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108634","article-title":"COVID-19: A review of therapeutic strategies and vaccine candidates","volume":"222","author":"Izda","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.04.049_b0015","first-page":"43","article-title":"Vaccines for COVID-19: The current state of play","volume":"35","author":"Koirala","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0020","article-title":"Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans","volume":"9","author":"Cagigi","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"7876","key":"10.1016\/j.vaccine.2023.04.049_b0025","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history of mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2023.04.049_b0030","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.4161\/rna.22269","article-title":"Developing mRNA-vaccine technologies","volume":"9","author":"Schlake","year":"2012","journal-title":"RNA Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.049_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/v13020270","article-title":"Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype","volume":"13","author":"Pascolo","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0040","article-title":"Review the safety of Covid-19 mRNA vaccines: a review","volume":"15","author":"Anand","year":"2021","journal-title":"Patient Saf Surg"},{"issue":"2","key":"10.1016\/j.vaccine.2023.04.049_b0045","article-title":"Clinical Advances in Viral-Vectored Influenza Vaccines","volume":"6","author":"Sebastian","year":"2018","journal-title":"Vaccines (Basel)"},{"issue":"10069","key":"10.1016\/j.vaccine.2023.04.049_b0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.049_b0055","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1","volume":"5","author":"Barouch","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.049_b0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/rccm.201603-0654OC","article-title":"Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial","volume":"195","author":"van Zyl-Smit","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.049_b0065","doi-asserted-by":"crossref","first-page":"e0256980","DOI":"10.1371\/journal.pone.0256980","article-title":"A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naive adults","volume":"16","author":"Sklar","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendonca","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.049_b0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.vaccine.2020.12.017","article-title":"Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy","volume":"39","author":"Holm","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.04.049_b0080","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2023.04.049_b0085","unstructured":"Kleiveland CR. Peripheral Blood Mononuclear Cells. In: Verhoeckx K, Cotter P, Lopez-Exposito I, Kleiveland C, Lea T, Mackie A et al, editors. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Cham (CH), Springer; 2015. Chapter 15."},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0090","doi-asserted-by":"crossref","DOI":"10.1186\/2050-7771-2-1","article-title":"Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases","volume":"2","author":"Yang","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.vaccine.2023.04.049_b0095","doi-asserted-by":"crossref","unstructured":"Jiang M, Kolehmainen P, Kakkola L, Maljanen S, Melen K, Smura T et al. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells. Microbiol Spectr 2021;9(1):e0077421,21. Epub 2021 Aug 11.","DOI":"10.1128\/Spectrum.00774-21"},{"key":"10.1016\/j.vaccine.2023.04.049_b0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fpubh.2020.00281","article-title":"A Perspective on Emerging Therapeutic Interventions for COVID-19","volume":"8","author":"Torequl Islam","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0022-3859.173187","article-title":"The clinical development process for a novel preventive vaccine: An overview","volume":"62","author":"Singh","year":"2016","journal-title":"J Postgrad Med"},{"issue":"27","key":"10.1016\/j.vaccine.2023.04.049_b0110","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.049_b0115","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0120","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25982-w","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil","volume":"12","author":"Clemens","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.049_b0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.049_b0130","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2023.04.049_b0135","article-title":"COVID-19 mRNA Vaccine and Myocarditis","volume":"8","author":"Singh","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.049_b0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","article-title":"Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review","volume":"36","author":"Kaur","year":"2021","journal-title":"Indian J Clin Biochem"},{"issue":"6","key":"10.1016\/j.vaccine.2023.04.049_b0145","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/CIRCULATIONAHA.121.056135","article-title":"Myocarditis With COVID-19 mRNA Vaccines","volume":"144","author":"Bozkurt","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.049_b0150","first-page":"e14099","article-title":"Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine","volume":"13","author":"Malayala","year":"2021","journal-title":"Cureus"},{"issue":"22","key":"10.1016\/j.vaccine.2023.04.049_b0155","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.04.049_b0160","unstructured":"Aleem A, Nadeem AJ. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). In: Anonymous StatPearls. Treasure Island (FL), StatPearls Publishing LLC, 2022."},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.049_b0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1189\/jlb.1003461","article-title":"Streptococcus pyogenes and Lactobacillus rhamnosus differentially induce maturation and production of Th1-type cytokines and chemokines in human monocyte-derived dendritic cells","volume":"75","author":"Veckman","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.049_b0170","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1189\/jlb.0307194","article-title":"Gene expression profiling during differentiation of human monocytes to macrophages or dendritic cells","volume":"82","author":"Lehtonen","year":"2007","journal-title":"J Leukoc Biol"},{"issue":"12","key":"10.1016\/j.vaccine.2023.04.049_b0175","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1089\/hum.1998.9.12-1769","article-title":"Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses","volume":"9","author":"Puumalainen","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.vaccine.2023.04.049_b0180","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab222","article-title":"A combination of N and S antigens with IgA and IgG measurement strengthens the accuracy of SARS-CoV-2 serodiagnostics","author":"Jalkanen","year":"2021","journal-title":"J Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2023.04.049_b0185","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1128\/JVI.79.15.9608-9617.2005","article-title":"Gene expression and antiviral activity of alpha\/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells","volume":"79","author":"Osterlund","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.049_b0190","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.4049\/jimmunol.150.5.1715","article-title":"Control of IFN-inducible MxA gene expression in human cells","volume":"150","author":"Ronni","year":"1993","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.vaccine.2023.04.049_b0195","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.vaccine.2023.04.049_b0200","first-page":"e11","article-title":"Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination","volume":"385","author":"Eichinger","year":"2021","journal-title":"Reply N Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2023.04.049_b0205","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMp068309","article-title":"Drug-induced immune-mediated thrombocytopenia\u2013from purpura to thrombosis","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0210","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02228-6","article-title":"Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection","volume":"20","author":"Ryan","year":"2022","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.04.049_b0215","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00954-7","article-title":"SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.vaccine.2023.04.049_b0220","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.vaccine.2023.04.049_b0225","doi-asserted-by":"crossref","unstructured":"Bos R, Rutten L, van der Lubbe JEM, Bakkers MJG, Hardenberg G, Wegmann F et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020;5:91,020-00243-x. eCollection 2020.","DOI":"10.1038\/s41541-020-00243-x"},{"issue":"4","key":"10.1016\/j.vaccine.2023.04.049_b0230","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","article-title":"Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19\/AZD1222 Vaccine","volume":"7","author":"Watanabe","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.vaccine.2023.04.049_b0235","article-title":"The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation","volume":"167280","author":"Rajah","year":"2021","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2023.04.049_b0240","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajem.2021.05.054","article-title":"Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines","volume":"49","author":"Long","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"22","key":"10.1016\/j.vaccine.2023.04.049_b0245","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2023.04.049_b0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.thromres.2021.10.027","article-title":"COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets","volume":"208","author":"Pitkanen","year":"2021","journal-title":"Thromb Res"},{"issue":"49","key":"10.1016\/j.vaccine.2023.04.049_b0255","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8213","article-title":"ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome","volume":"7","author":"Baker","year":"2021","journal-title":"Sci Adv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23004632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:42Z","timestamp":1759404342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23004632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":51,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0264410X23004632"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.049","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 adenovirus vector vaccine induces higher interferon and pro-inflammatory responses than mRNA vaccines in human PBMCs, macrophages and moDCs","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}